204 related articles for article (PubMed ID: 11499181)
21. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
Grenader T; Peretz T; Lifchitz M; Shavit L
Breast; 2005 Aug; 14(4):264-8. PubMed ID: 16085232
[TBL] [Abstract][Full Text] [Related]
23. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma.
Kim YT; Nam EJ; Yoon BS; Kim SW; Kim SH; Kim JH; Kim HK; Koo JS; Kim JW
Gynecol Oncol; 2005 Dec; 99(3):585-90. PubMed ID: 16084575
[TBL] [Abstract][Full Text] [Related]
24. Update on the management of ovarian cancer.
Ozols RF
Cancer J; 2002; 8 Suppl 1():S22-30. PubMed ID: 12075699
[TBL] [Abstract][Full Text] [Related]
25. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
[TBL] [Abstract][Full Text] [Related]
26. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
[TBL] [Abstract][Full Text] [Related]
27. Achievements and unmet needs in the management of advanced ovarian cancer.
Guarneri V; Piacentini F; Barbieri E; Conte PF
Gynecol Oncol; 2010 May; 117(2):152-8. PubMed ID: 20056266
[TBL] [Abstract][Full Text] [Related]
28. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of risk factors for epithelial ovarian cancer recurrence].
Liu S; Liu JH; Huang H; Peng XP; Wang YM
Ai Zheng; 2003 Nov; 22(11):1197-200. PubMed ID: 14613652
[TBL] [Abstract][Full Text] [Related]
31. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
32. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
33. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
Wu M; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
[TBL] [Abstract][Full Text] [Related]
34. [Neoadjuvant chemotherapy for advanced epithelial ovarian cancer].
Hatae M; Onishi Y; Nakamura T; Yamamoto H; Kusumoto M; Matsui T; Mihara K; Taniguchi H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1833-7. PubMed ID: 11729475
[TBL] [Abstract][Full Text] [Related]
35. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
36. [Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer].
Plaisant N; Quenet F; Fabbro M; Gourgou S; Gutowski M; Saint-Aubert B; Rouanet P
Gynecol Obstet Fertil; 2004 May; 32(5):391-7. PubMed ID: 15177208
[TBL] [Abstract][Full Text] [Related]
37. Advances in the understanding of risk factors for ovarian cancer.
Bandera CA
J Reprod Med; 2005 Jun; 50(6):399-406. PubMed ID: 16050564
[TBL] [Abstract][Full Text] [Related]
38. Advances in treatment of epithelial ovarian cancer.
Kikkawa F; Nawa A; Ino K; Shibata K; Kajiyama H; Nomura S
Nagoya J Med Sci; 2006 Jan; 68(1-2):19-26. PubMed ID: 16579172
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
[TBL] [Abstract][Full Text] [Related]
40. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]